[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424.
[2] Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017; 66(4):683-691.
[3] Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014; 383(9927):1490-1502.
[4] Dekker E, Rex DK. Advances in CRC Prevention: Screening and Surveillance. Gastroenterology. 2018; 154(7):1970-1984.
[5] Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64(10):1637-1649.
[6] Neureiter D, Jäger T, Ocker M, et al. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol. 2014;20: 7830-7848.
[7] Michalak EM, Burr ML, Bannister AJ, et al. The roles of DNA, RNA and histone methylation in ageing and cancer. Nat. Rev. Mol. Cell Biol. 2019; 20(10):573-589.
[8] Cech TR, Steitz JA. The noncoding RNA revolution-trashing old rules to forge new ones. Cell. 2014; 157:77-94.
[9] Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505:344-352.
[10] Marchese FP, Huarte M. Long non-coding RNAs and chromatin modifiers: their place in the epigenetic code. Epigenetics. 2014; 9(1):21-26.
[11] Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat. Rev. Genet. 2016; 17(5):272-283.
[12] Wang P, Xue Y, Han Y, et al. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science. 2014; 344(6181):310-313.
[13] Prensner JR, Iyer MK, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet. 2013; 45:1392-1398.
[14] Hung CL, Wang LY, Yu YL, et al. A long noncoding RNA connects c-Myc to tumor metabolism. Proc. Natl. Acad. Sci. USA. 2014; 111(52):18697-18702.
[15] Hu T, Lu Y. BCYRN1, a c-MYC-activated long non-coding RNA, regulates cell metastasis of non-small-cell lung cancer. Cancer Cell Int. 2015; 15:36.
[16] Booy EP, McRae EK, Koul A, et al. The long non-coding RNA BC200 (BCYRN1) is critical for cancer cell survival and proliferation. Mol. Cancer. 2017; 16(1):109.
[17] Ding S, Jin Y, Hao Q, et al. LncRNA BCYRN1/miR-490-3p/POU3F2, served as a ceRNA network, is connected with worse survival rate of hepatocellular carcinoma patients and promotes tumor cell growth and metastasis. Cancer Cell Int. 2020; 20:6.
[18] Zhai H, Li Y. BCYRN1 is correlated with progression and prognosis in gastric cancer. Biosci. Rep. 2019; 39(11):BSR20190505.
[19] Wang YC, Chuang YH, Shao Q, et al. Brain cytoplasmic RNA 1 suppresses smooth muscle differentiation and vascular development in mice. J. Biol. Chem. 2018; 293(15):5668-5678.
[20] Zhang XY, Tang XY, Ma LJ, et al. Schisandrin B down-regulated lncRNA BCYRN1 expression of airway smooth muscle cells by improving miR-150 expression to inhibit the proliferation and migration of ASMC in asthmatic rats. Cell Prolif. 2017; 50(6):e12382.
[21] Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat. Genet. 2009; 10:94-108.
[22] Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350-355.
[23] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
[24] Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433:769-773.
[25] Ren XS, Tong Y, Qiu Y, et al. MiR155-5p in adventitial fibroblasts-derived extracellular vesicles inhibits vascular smooth muscle cell proliferation via suppressing angiotensin-converting enzyme expression. J.Extracell.Vesicles. 2019; 9(1):1698795.
[26] Necsulea A, Soumillon M, Warnefors M, et al. The evolution of lncRNA repertoires and expression patterns in tetrapods. Nature. 2014; 505(7485):635-640.
[27] Qu L, Ding J, Chen C, et al. Exosome-Transmitted lncARSR Promotes Sunitinib Resiistance in Renal Cancer by Acting as a Competing Endogenous RNA. Cancer Cell. 2016; 29(5):653-668.
[28] Gates EDH, Lin JS, Weinberg JS, et al. Guiding the first biopsy in glioma patients using estimated Ki-67 maps derived from MRI: conventional versus advanced imaging, Neuro-Oncology. 2019; 21(4):527-536.
[29] Pan Z, Cai J, Lin J, et al. A novel protein encoded by circFNDC3B inhibits tumor progression and EMT through regulating Snail in colon cancer. Mol Cancer. 2020; 19(1).
[30] Nagaraju GP, EI-Rayes BF. Cyclooxygenase-2 in gastrointestinal malignancies. Cancer. 2019; 125(8):1221-1227.
[31] La Rocca G, Pucci-Minafra I, Marrazzo A, et al. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br. J. Cancer. 2004; 90(7):1414-1421.
[32] Hu L, Chen M, Chen X, et al. Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate. Cell Death Dis. 2020; 11(4):281.
[33] Walensky LD. Targeting BAX to drug death directly. Nat Chem Biol. 2019; 15:657-665.
[34] Terhune PG, Phifer DM, Tosteson TD, et al. K-ras mutations in focal proliferation lesions of human pancreas. Cancer Epidemiol. Biomarkers Prev. 1998; 7(6).
[35] Siegel RL, Miller KD, Jemal A, et al. Cancer statistics. CA Cancer J Clin. 2017; 67:7-30.
[36] Punt CJA, Koopman M, Vermeulen L, et al. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol 2017; 14:235-246.
[37] Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers. 2015; 1:15065.
[38] Yang L, Lin C, Jin C, et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013; 500:598-602.
[39] Lorenzen J, Thum T. Long noncoding RNAs in kidney and cardiovascular diseases. Nat. Rev. Nephrol. 2016; 12:360-373.
[40] Yu W, Xiang D, Jia H, et al. The lncRNA BCYRN1 Functions as an Oncogene in Human Glioma by Downregulating miR-125a-5p in vitro. Cancer Manag Res. 2020; 12:1151-1161.
[41] Lang N, Wang C, Zhao J, et al. Long non‑coding RNA BCYRN1 promotes glycolysis and tumor progression by regulating the miR‑149/PKM2 axis in non‑small‑cell lung cancer. Molecular Medicine Reports. 2020; 21(3):1509-1516.
[42] Gu L, Lu L, Zhou D, et al. Long Noncoding RNA BCYRN1 Promotes the Proliferation of Colorectal Cancer Cells via Up-Regulating NPR3 Expression. Cell Physiol Biochem. 2018; 48(6):2337-2349.
[43] Yu JH, Chen Y. Clinical significance of lncRNA BCYRN1 in colorectal cancer and its role in cell metastasis. Eur Rev Med Pharmacol Sci. 2019; 23(21):9371-9378.
[44] Suzuki HI, Miyazono K. Emerging complexity of microRNA generation cascades. J Biochem. 2011; 149:15-25.
[45] Newman MA, Hammond SM. Emerging paradigms of regulated microRNA processing. Genes Dev. 2010; 24:1086-1092.
[46] Cui ZH, Shen SQ, Chen ZB, et al. Growth inhibition of hepatocellular carcinoma tumor endothelial cells by miR-204-3p and underlying mechanism. World J. Gastroenterol. 2014; 20(18):5493-5504.
[47] Yuan D, Qian H, Guo T, et al. LncRNA-ATB Promotes the Tumorigenesis of Ovarian Cancer via Targeting miR-204-3p. Onco Targets Ther. 2020; 13:573-583.
[48] Yang S, Liu T, Sun Y, et al. The long noncoding RNA LINC00483 promotes lung adenocarcinoma progression by sponging miR-204-3p. Cell. Mol. Biol. Lett. 2019; 24:70.
[49] Guo J, Zhao P, Liu Z, et al. MiR-2014-3p Inhibited the Proliferation of Bladder Cancer Cells via Modulating Lactate Dehydrogenase-Mediated Glycolysis. Front Oncol. 2019; 9:1242.